Search trials – HealthDB

AI · alzheimer

Намерени 72 изпитвания за "alzheimer" Стр. 1 от 4

Recruiting Phase 3

Effect of CAFfeine on Cognition in Alzheimer's Disease

Alzheimer Disease

Sporadic Alzheimer's disease is a multifactorial illness arising a major medico-economic stakes for our aging societies. There is currently no curative treatment available. Coffee is a complex beverage with psychostimulant properties whose main effective element, caffeine, has a pleiotropic effect on the central nervous system. Caffeine pharmacological properties enable its use like an Alzheimer's disease symptomatic treatment. Its supposed benefits mustn't obscure anxiety and insomnia caffeine effect at large dose, which Alzheimer's patients might be more vulnerable. The main study objective is to evaluate placebo-controlled caffeine efficacy (30 treatments weeks) on cognitive decline in Alzheimer's disease dementia at beginning to moderate stage (MMSE 16-24).

Начало: 01.03.2021 Край: 01.12.2027 Възраст: от 50 г.

France University Hospital, Lille NCT04570085

Recruiting Phase 3

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

Psychosis Associated With Alzheimer's Disease

This is a Phase 3, 38-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with psychosis associated with Alzheimer's Disease. The primary objective of the study is to evaluate relapse prevention in subjects with psychosis associated with Alzheimer's Disease treated with KarXT compared to placebo. The secondary objectives of the study are to evaluate the time from randomization to discontinuation for any reason or relapse and safety and tolerability in subjects with psychosis associated with Alzheimer's Disease treated with KarXT compared to placebo.

Начало: 23.08.2022 Край: 05.10.2026 Възраст: 55–90 г.

Bulgaria, Croatia, Czechia +8 Karuna Therapeutics, Inc., a Bristol Myers Squibb compa NCT05511363

Recruiting Phase 1/2

Biomarker-based Trial of NPC-1 for Alzheimer's Pathology

Alzheimer Disease Mild Cognitive Impairment (MCI) Subjective Cognitive Complaints (SCCs)

The goal of this early phase, open-label, single arm clinical trial is to determine the 6-month effects and tolerability of NPC1 (parthenolide and ipriflavone) on biomarkers of Alzheimer's Disease among adults with objective indicators of seeding AD pathology that also have subjective cognitive concerns, Mild Cognitive Impairment, or Alzheimer's Disease (AD)

Начало: 01.04.2026 Край: 01.06.2027 Възраст: от 55 г.

United States Massachusetts General Hospital NCT07236190

Recruiting

Dominantly Inherited Alzheimer Network (DIAN)

Alzheimer's Disease

The purpose of this study is to identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.

Начало: 01.01.2009 Край: 01.07.2026 Възраст: от 18 г.

Argentina, Australia, Brazil +10 Washington University School of Medicine NCT00869817

Recruiting Phase 1

Alzheimer's Disease and Faecal Microbiota Transplantation -a Pilot Study

Alzheimer s Disease Faecal Microbiota Transplantation (FMT)

The goal of this study is to assess the feasibility and safety of faecal microbiota transplantation for Alzheimer's disease.

Начало: 01.05.2026 Край: 01.01.2027 Възраст: от 18 г.

Norway University Hospital of North Norway NCT07332260

Recruiting Phase 1

PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)

Alzheimer s Disease Mild Cognitive Impairment Healthy

Background: About 5 million adults in the United States have age-related brain disorders. These include Alzheimer disease (AD), mild cognitive impairment (MCI), and other dementias. The number of people with these disorders will likely increase as the population ages and life span increases. Inflammation is thought to play a role in AD and MCI. Researchers want to know if an enzyme called PDE4B increases inflammation in people with AD or MCI. Objective: To test whether medical imaging using a new radiotracer (\[18F\]PF-06445974) can measure PDE4B in the brains of people with AD or MCI. Eligibility: People aged 50 years and older with AD or MCI. Healthy volunteers are also needed. Design: Participants will have up to 5 clinic visits with 3 imaging scans of the brain. They will have be screened. They will have a physical exam with blood tests. This will include tests of their heart and nerve function, including memory. Participants will have 2 positron emission tomography (PET) scans. One will use a standard radiotracer. The other will use the study radiotracer. They will receive each tracer through a tube attached to a needle inserted into a vein. During the scan with the study tracer, participants will have a second tube inserted into a vein in the wrist; this tube will be used to draw blood during the scan. Participants will lie on a bed that slides into a doughnut-shaped machine. These visits will take about 6 hours each. Participants will have 1 magnetic resonance imaging (MRI) scan. They will lie on a bed that slides into a cylinder. This visit will take up to 2 hours....

Начало: 29.04.2026 Край: 11.04.2030 Възраст: 50–100 г.

United States National Institute of Mental Health (NIMH) NCT07169630

Recruiting Phase 3

A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)

Alzheimer Disease Psychosis

The purpose of this study is to evaluate KarXT + KarX-EC as a treatment for psychosis associated with Alzheimer's disease.

Начало: 25.03.2026 Край: 20.03.2028 Възраст: 55–90 г. Treatment

Australia, Canada, Japan +2 Bristol-Myers Squibb NCT06947941

Recruiting Phase 1/2

Stem Cell Therapy for Early Alzheimer's Disease

Cognitive Dysfunction

The goal of this clinical trial is to learn if stem cell therapy works to treat brain inflammation in adults. Inflammation in the brain may be involved in adults who have memory or thinking problems. The stem cells will be taken from participant's fat samples, processed and given back to participants, so they are their own donor. The main questions this trial aims to answer are: * Does stem cell therapy reduce inflammation in the brain? * Does stem cell therapy improve brain activity? * Does stem cell therapy slow down progression to Alzheimer's disease? Participants will: * Have a small fat biopsy taken at a doctor's office to process stem cells * Receive 4 infusions of stem cells, through a vein in the arm over 12 weeks * Visit the clinic every 2-4 weeks for the first 4 months and then every 1-2 months for 8 months for checkups and tests

Начало: 11.03.2026 Край: 01.01.2028 Възраст: 60–80 г.

United States Paul E Schulz NCT06775964

Recruiting Phase 2/3

Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia

Agitation Associated With Alzheimer's Disease Dementia

The goal of this clinical trial is to evaluate the safety and efficacy of EXV-802 and EXV-801 in treatment of agitation in participants with Alzheimer's Disease dementia.

Начало: 02.02.2026 Край: 01.02.2029 Възраст: 55–90 г.

Canada, United Kingdom, United States Exciva GmbH NCT07284472

Recruiting Phase 3

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

Alzheimer Disease Agitation

The purpose of this study is to evaluate the long-term efficacy and safety of combined formulation of xanomeline tartrate/trospium chloride in an immediate release (IR) capsule (KarXT) and xanomeline enteric capsules (KarX-EC) in participants with agitation associated with Alzheimer's Disease who completed the parent studies CN012-0023 or CN012-0024.

Начало: 02.12.2025 Край: 20.07.2029 Възраст: 55–90 г.

Argentina, Brazil, Bulgaria +22 Bristol-Myers Squibb NCT06937229

Recruiting Phase 1/2

Study of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease

Alzheimer Disease Alzheimer Disease, Early Onset

Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of ARO-MAPT-SC compared to placebo in adult healthy volunteers and in participants with early Alzheimer's disease (AD), defined as mild cognitive impairment due to AD and mild AD dementia.

Начало: 18.11.2025 Край: 01.06.2027 Възраст: 18–80 г. Treatment

New Zealand Arrowhead Pharmaceuticals NCT07221344

Recruiting Phase 3

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

Alzheimers Disease

The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD).

Начало: 12.11.2025 Край: 07.06.2028 Възраст: 50–90 г. Treatment

Argentina, Australia, Brazil +12 Hoffmann-La Roche NCT07170150

Recruiting Phase 1

A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

Alzheimer's Disease

The purpose of this study is to: * Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD) * Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after dose administration

Начало: 15.10.2025 Край: 06.03.2030 Възраст: 40–80 г.

Canada, Netherlands, Spain +1 Alnylam Pharmaceuticals NCT07214727

Recruiting Phase 1/2

A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease

Alzheimer Disease

The purpose of this study is to evaluate the safety and tolerability of NSC001 on in patients with mild to moderate Alzheimer's disease and to evaluate the influence of the compound on cognitive function.

Начало: 25.08.2025 Край: 30.09.2026 Възраст: 50–85 г.

Austria, Germany NSC-Therapeutics NCT06995573

Recruiting Phase 2

Open-label Extension Study in Participants With Early Alzheimer's Disease

Alzheimer's Disease

The study medicine GSK4527226 is being studied in participants with Alzheimer's Disease (AD) in study 219867 (the parent study, NCT06079190). This new study is an extension of that parent study called an open-label extension (OLE). An OLE is a clinical trial where all participants receive the same study medicine. Participants must already be in study 219867 to be able to take part in this study. This study will assess the long-term safety and efficacy of GSK4527226 in participants with early AD (including mild cognitive impairment \[MCI\] and mild dementia due to AD) who have completed the parent study.

Начало: 14.08.2025 Край: 08.12.2028 Възраст: 50–85 г. Treatment

Argentina, Australia, Canada +8 GlaxoSmithKline NCT07105709

Recruiting Phase 3

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

Alzheimer's Disease

The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease

Начало: 21.07.2025 Край: 23.02.2029 Възраст: 60–85 г. Treatment

Argentina, Australia, Brazil +13 Bristol-Myers Squibb NCT06976203

Recruiting Phase 3

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)

Alzheimer Disease

The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

Начало: 16.07.2025 Край: 13.11.2028 Възраст: 55–90 г.

Argentina, Chile, Czechia +11 Bristol-Myers Squibb NCT07011745

Recruiting Phase 2

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

Early Alzheimer's Disease

Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech), and decision-making skills. It can limit a person's ability to do daily tasks. MK-2214 is a study treatment designed to slow down AD. The goals of the study are to learn: * If MK-2214 slows the spread of tau in the brain compared to placebo. Tau is a protein that accumulates in AD \& damages brain cells. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of a study treatment. * About the safety of MK-2214 and if people tolerate it

Начало: 16.07.2025 Край: 30.04.2029 Възраст: 50–85 г. Treatment

Argentina, Australia, Belgium +6 Merck Sharp & Dohme LLC NCT07033494

Recruiting Phase 3

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

Alzheimer's Disease

The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease

Начало: 14.07.2025 Край: 23.02.2029 Възраст: 60–85 г. Treatment

Argentina, Australia, Brazil +14 Bristol-Myers Squibb NCT06976216

Recruiting Phase 3

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

Alzheimer Disease

The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

Начало: 10.07.2025 Край: 08.12.2028 Възраст: 55–90 г.

Argentina, Brazil, Bulgaria +12 Bristol-Myers Squibb NCT07011732

1 2 3 4